Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewSJ 11646 is a potent LCK (lymphocyte-specific protein tyrosine kinase) Degrader (PROTAC®; DC50 = 0.00838 pM). It comprises Dasatinib (Cat. No. 6793), as the LCK ligand, and a phenyl glutarimide-based cereblon binder. It shows cytotoxicity in LCK-activated T cell acute lymphoblastic leukemia (T-ALL) cell lines and primary leukemia samples in vitro. In vivo, SJ11646 shows anti-leukemic efficacy in patient-derived xenograft models of T-ALL.
LCK antibodies validated for Simple Western™ (automated Western) instruments and Western Blot also available: Catalog # AF3704 and MAB37041.
PROTAC® is a registered trademark of Arvinas Operations, Inc., and is used under license.
Sold under license from St. Jude Children's Research Hospital.
M. Wt | 746.28 |
Formula | C36H40ClN9O5S |
Storage | Store at -20°C |
Purity | ≥98% (HPLC) |
CAS Number | 2933135-82-9 |
InChI Key | AJNQGWOQPRWRML-UHFFFAOYSA-N |
Smiles | CC1=NC(NC2=NC=C(C(NC3=C(C=CC=C3Cl)C)=O)S2)=CC(N4CCN(CC4)CCCNC(COC5=CC=C(C=C5)C6CCC(NC6=O)=O)=O)=N1 |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solvent | Max Conc. mg/mL | Max Conc. mM | |
---|---|---|---|
Solubility | |||
DMSO | 14.93 | 20 |
The following data is based on the product molecular weight 746.28. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
0.2 mM | 6.7 mL | 33.5 mL | 67 mL |
1 mM | 1.34 mL | 6.7 mL | 13.4 mL |
2 mM | 0.67 mL | 3.35 mL | 6.7 mL |
10 mM | 0.13 mL | 0.67 mL | 1.34 mL |
References are publications that support the biological activity of the product.
Hu et al (2022) Preclinical evaluation of proteolytic targeting of LCK as a therapeutic approach in T cell acute lymphoblastic leukemia. Sci.Transl.Med. 14 eabo5228 PMID: 36001679
If you know of a relevant reference for SJ 11646, please let us know.
Keywords: SJ 11646, SJ 11646 supplier, SJ11646, potent, lymphocyte, specific, kinase, Lck, degraders, degrades, targeted, protein, degradation, TPD, kinases, PROTAC, acute, lymphoblastic, leukemia, T-ALL, Src, Kinases, Kinase, Degraders, 7721, Tocris Bioscience
Citations are publications that use Tocris products.
Currently there are no citations for SJ 11646. Do you know of a great paper that uses SJ 11646 from Tocris? Please let us know.
There are currently no reviews for this product. Be the first to review SJ 11646 and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
This brochure highlights the tools and services available from Bio-Techne to support your Targeted Protein Degradation and Induced Proximity research, including:
Degraders (e.g. PROTACs) are bifunctional small molecules, that harness the Ubiquitin Proteasome System (UPS) to selectively degrade target proteins within cells. They consist of three covalently linked components: an E3 ubiquitin ligase ligand, a linker and a ligand for the target protein of interest. Authored in-house, this poster outlines the generation of a toolbox of building blocks for the development of Degraders. The characteristics and selection of each of these components are discussed. Presented at EFMC 2018, Ljubljana, Slovenia